NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG, HZRM Haemophilie-Zentrum Rhein Main GmbH, Emory University

Conditions

Haemophilia AType 3 Von Willebrand Disease

Phase 3

A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients with Type 3 Von Willebrand Disease

RecruitingCTIS2024-515622-80-00

F. Hoffmann-La Roche AGType 3 Von Willebrand Disease

Start: 2025-06-04Target: 47Updated: 2025-06-27

Phase 4

MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial

RecruitingCTIS2024-516741-39-00

HZRM Haemophilie-Zentrum Rhein Main GmbH, Emory UniversityHaemophilia A

Start: 2020-01-14Target: 22Updated: 2025-10-28